Autoimmune Disease – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Thu, 03 Jun 2021 20:48:39 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Autoimmune Disease – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases https://www.cannabisclinicians.org/2021/06/03/therapeutic-prospects-of-cannabinoids-in-the-immunomodulation-of-prevalent-autoimmune-diseases/ Thu, 03 Jun 2021 19:07:57 +0000 https://www.cannabisclinicians.org/?p=23209 Cannabinoids such as ▵-9-THC and CBD can downregulate the immune response by modulating the endocannabinoid system. This modulation is relevant for the treatment of prevalent autoimmune diseases (ADs), such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), diabetes mellitus type 1 (DMT1), and rheumatoid arthritis (RA). These conditions require new therapeutic options with fewer side effects for the control of the autoimmune response. Objective: to conduct a literature review of preclinical scientific evidence that supports further clinical investigations for the use of cannabinoids (natural or synthetic) as potential immunomodulators of the immune response in ADs.

The post Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases appeared first on Society of Cannabis Clinicians.

]]> Immune Responses Regulated by Cannabidiol. https://www.cannabisclinicians.org/2019/09/04/immune-responses-regulated-by-cannabidiol/ Wed, 04 Sep 2019 12:46:28 +0000 https://www.cannabisclinicians.org/?p=15229 Authors: James M. Nichols and Barbara L.F. Kaplan
Cannabis and Cannabinoid Research, 4 September 2019
---
Introduction: Cannabidiol (CBD) as Epidiolex® (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabi...

The post Immune Responses Regulated by Cannabidiol. appeared first on Society of Cannabis Clinicians.

]]> The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity. https://www.cannabisclinicians.org/2018/04/06/ms-spasticity-cannabis-and-driving/ Fri, 06 Apr 2018 18:30:32 +0000 http://cannabisclinicians.org/?p=5787 Authors: Elisabeth G. Celius, Carlos Vila
Brain and Behavior, 6 April 2018
---
BACKGROUND: Driving ability is a key function for the majority of patients with multiple sclerosis (MS) to help maintain daily interactions. Both physical and cognitive disability, as well as treatments, may affect the ability to drive. Spasticity is a common symptom associate...

The post The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity. appeared first on Society of Cannabis Clinicians.

]]> Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. https://www.cannabisclinicians.org/2017/11/06/oral-administration-of-cannabis-with-lipids-leads-to-high-levels-of-cannabinoids-in-the-intestinal-lymphatic-system-and-prominent-immunomodulation/ Mon, 06 Nov 2017 14:06:44 +0000 https://www.cannabisclinicians.org/?p=14719 Authors: Atheer Zgair, Jong Bong Lee, Jonathan C. M. Wong, Dhiaa A. Taha, Jehan Aram, et al
Scientific Reports, 6 November 2017
---
Cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) have well documented immunomodulatory effects in vitro, but not following oral administration in humans. Here we show that oral co-administration of cannabinoids with lipids can substantially increase their intestinal lympha...

The post Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. appeared first on Society of Cannabis Clinicians.

]]> Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. https://www.cannabisclinicians.org/2016/11/01/randomized-controlled-trial-of-sativex-to-treat-detrusor-overactivity-in-multiple-sclerosis/ Tue, 01 Nov 2016 19:54:34 +0000 https://www.cannabisclinicians.org/?p=14702 Authors: R. B. C. Kavia, D. De Ridder, C. S. Constantinescu, C. G. Stott, C. J. Fowler
Multiple Sclerosis Journal, November 2016
---
BACKGROUND: Bladder dysfunction is a common feature of multiple sclerosis (MS). OBJECTIVE: In this study we aimed to assess the efficacy, tolerability and safety of Sativex(®) (nabiximols) as an add-on therapy in alleviating bladder symptoms in patients with MS. METHODS: We un...

The post Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. appeared first on Society of Cannabis Clinicians.

]]> Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. https://www.cannabisclinicians.org/2016/07/01/clinical-endocannabinoid-deficiency-reconsidered-current-research-supports-the-theory-in-migraine-fibromyalgia-irritable-bowel-and-other-treatment-resistant-syndromes/ Fri, 01 Jul 2016 17:03:54 +0000 https://www.cannabisclinicians.org/?p=15015 Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016
---
Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p...

The post Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. appeared first on Society of Cannabis Clinicians.

]]> Cannabinoids and autoimmune diseases: A systematic review https://www.cannabisclinicians.org/2016/06/01/cannabinoids-and-autoimmune-diseases-a-systematic-review/ Wed, 01 Jun 2016 19:48:41 +0000 https://www.cannabisclinicians.org/?p=14700 Authors: Valeria Katchan, Paula David, Yehuda Shoenfeld
Autoimmunity Reviews, June 2016
---
Cannabinoids have shown to have a variety effects on body systems. Through CB1 and CB2 receptors, amongst other, they exert an effect by modulating neurotransmitter and cytokine release. Current research in the role of cannabinoids in the immune system shows that they possess...

The post Cannabinoids and autoimmune diseases: A systematic review appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. https://www.cannabisclinicians.org/2015/10/01/cannabidiol-for-the-prevention-of-graft-versus-host-disease-after-allogeneic-hematopoietic-cell-transplantation-results-of-a-phase-ii-study/ Thu, 01 Oct 2015 19:41:08 +0000 https://www.cannabisclinicians.org/?p=14698 Authors: Moshe Yeshurun, Ofer Shpilberg, Corina Herscovici, Liat Shargian, Juliet Dreyer, et al
Biology of Blood and Marrow Transplantation, October 2015
---
Graft-versus-host-disease (GVHD) is a major obstacle to successful allogeneic hematopoietic cell transplantation (alloHCT). Cannabidiol (CBD), a nonpsychotropic ingredient of Cannabis sativa, possesses potent anti-inflammatory and immunosuppressive properties. We hypothesized...

The post Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. appeared first on Society of Cannabis Clinicians.

]]> Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells. https://www.cannabisclinicians.org/2015/09/01/%ce%b4%e2%81%b9-tetrahydrocannabinol-attenuates-allogeneic-host-versus-graft-response-and-delays-skin-graft-rejection-through-activation-of-cannabinoid-receptor-1-and-induction-of-myeloid-derived-supp/ Tue, 01 Sep 2015 19:14:22 +0000 https://www.cannabisclinicians.org/?p=14694 Authors: Jessica M. Sido, Prakash S. Nagarkatti, Mitzi Nagarkatti
Journal of Leukocyte Biology, September 2015
---
Immune cells have been shown to express cannabinoid receptors and to produce endogenous ligands. Moreover, activation of cannabinoid receptors on immune cells has been shown to trigger potent immunosuppression. Despite such studies, the role of cannabinoids in transplantation...

The post Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells. appeared first on Society of Cannabis Clinicians.

]]> Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. https://www.cannabisclinicians.org/2015/06/23/medical-marijuana-for-treatment-of-chronic-pain-and-other-medical-and-psychiatric-problems/ Tue, 23 Jun 2015 16:16:18 +0000 http://cannabisclinicians.org/?p=10327 Authors: Kevin P. Hill
JAMA, 23 June 2015
---
IMPORTANCE: As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE: To review the pharmacology, indications, and law...

The post Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. appeared first on Society of Cannabis Clinicians.

]]>